• Explore /
  • Poster
  • / Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial.

Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial.

Abstract Poster

Authors

Karen Kelly

Karen Kelly

UC Davis Comprehensive Cancer Center, Sacramento, CA

Karen Kelly , Christopher Ryan Heery , Manish R. Patel , Jeffrey R. Infante , Nicholas Iannotti , Joseph W. Leach , Ding Wang , Jason Claud Chandler , Hendrik-Tobias Arkenau , Matthew H. Taylor , Michael S. Gordon , Deborah Jean Lee Wong , Howard Safran , Howard Kaufman , Ulrich Keilholz , Marcis Bajars , Anja von Heydebreck , Isabell Speit , Jean-Marie Cuillerot , James L. Gulley

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT01772004

Citation

J Clin Oncol 34, 2016 (suppl; abstr 3055)

DOI

10.1200/JCO.2016.34.15_suppl.3055

Abstract #

3055

Poster Bd #

377

Abstract Disclosures

Similar Posters

First Author: Claire F. Verschraegen

First Author: Hyun Cheol Chung

First Author: Andrea B. Apolo

First Author: Christophe Le Tourneau